Oruka Therapeutics Files 8-K on Officer/Director Changes
Ticker: ORKA · Form: 8-K · Filed: Dec 11, 2025 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Oruka Therapeutics, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $10 billion, $40,000, $12,000, $7,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financial-statements
Related Tickers: ORKA
TL;DR
Oruka Therapeutics (ORKA) filed an 8-K detailing leadership changes and financial statements.
AI Summary
Oruka Therapeutics, Inc. filed an 8-K on December 11, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits. Oruka Therapeutics, Inc. was formerly known as ARCA biopharma, Inc., NUVELO INC, and HYSEQ INC.
Why It Matters
This filing provides updates on the company's leadership and governance, which can impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing leadership changes and financial statements, not indicating immediate operational or financial distress.
Key Players & Entities
- Oruka Therapeutics, Inc. (company) — Registrant
- ARCA biopharma, Inc. (company) — Former company name
- NUVELO INC (company) — Former company name
- HYSEQ INC (company) — Former company name
- December 11, 2025 (date) — Date of earliest event reported
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided text.
What is the primary business of Oruka Therapeutics, Inc.?
Oruka Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
When did Oruka Therapeutics, Inc. change its name from ARCA biopharma, Inc.?
The date of the name change from ARCA biopharma, Inc. was January 28, 2009.
What is the business address of Oruka Therapeutics, Inc.?
The business address is 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.
What other former company names has Oruka Therapeutics, Inc. had?
Besides ARCA biopharma, Inc., Oruka Therapeutics, Inc. was formerly known as NUVELO INC and HYSEQ INC.
Filing Stats: 1,041 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-12-11 16:10:55
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value ORKA The Nasdaq Global Ma
- $10 billion — quired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Of
- $40,000 — n annual cash retainer in the amount of $40,000 for his service as a member of the Boar
- $12,000 — n annual cash retainer in the amount of $12,000 for his service as Chair of the Compens
- $7,500 — Chair of the Compensation Committee and $7,500 for his service as a member of the Audi
Filing Documents
- ea0268925-8k_oruka.htm (8-K) — 45KB
- ea026892501ex10-1_oruka.htm (EX-10.1) — 13KB
- ex10-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-120676.txt ( ) — 235KB
- orka-20251211.xsd (EX-101.SCH) — 3KB
- orka-20251211_lab.xml (EX-101.LAB) — 33KB
- orka-20251211_pre.xml (EX-101.PRE) — 22KB
- ea0268925-8k_oruka_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Offer Letter, dated December 1, 2025, between Oruka Therapeutics, Inc. and Chris Martin. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oruka Therapeutics, Inc. Date: December 11, 2025 By: /s/ Paul Quinlan Paul Quinlan General Counsel 2